Amgen is investing 600 million US dollars in new F&E systems in California
Building a new, state-of-the-art science and innovation center in the global headquarters of Amgen in Thousand Oaks, California.
With kind permission: Amgen
Amgen On Tuesday there was known that there will be more than 600 million US dollars for the construction of a new research and development facility in its headquarters in Thousand Oaks, California, the youngest in a number of new US investments in the pharmaceutical industry.
The drug manufacturers have tried to strengthen their presence in the USA because President Donald Trump threatens to capture the industry with tariffs for pharmaceuticals imported into the country. Trump said that these taxes will encourage companies to remind production at a time at a time at which the production of domestic medications has shrunk dramatically in the past ten years.
In a publication, Amgen said that the construction of the facility would begin in the third quarter of this year and create hundreds of US jobs.
In particular, the facility is not a production facility, but it will enable researchers, engineers and scientists to find medication of the next generation for patients with “the most serious diseases”, the company said. Amgen said the building has “progressive automation and digital functions”, which scientists offer the necessary instruments for this research and development.
“At Amgen we continue to invest in the future of American science and innovation,” said CEO Bob Bradway in the publication. “The center will enable our scientists to form the instruments and the collaborative environment that they need to form the next era of scientific discovery and promote medication that improve human health.”
Amgen said that almost 5 billion US dollars has invested in direct US capital expenses since 2017’s law. In April, the company announced an extension of the Ohio Biotech Manufacturing Facility by 900 million US dollars. In December, the drug maker announced that he would spend 1 billion US dollar for the construction of a second drug substance system in Holly Springs, North Carolina.
These investments are made after the US Food and Drug Administration launched a program in August that should make it easier for companies to set up new pharmaceutical manufacturing facilities in the USA. The White House estimates can currently take five to ten years to build new production capacities for pharmaceuticals, which are previously referred to as “unacceptable from a national point of view”.
